MOUNTAIN VIEW, Calif.
Oct. 1, 2013
/PRNewswire/ -- Advancements in pump technology, especially in terms of specialized functionalities such as infusion rate detection and dosage mismatch alerts, sustain the mature, replacement-intensive infusion pumps market in the U.S. In particular, the ambulatory and insulin pump segments are poised for significant growth despite reimbursement restrictions and government initiatives to lower overall healthcare costs.
New analysis from Frost & Sullivan's (
Strategic Analysis of the US Infusion Pumps Market
research finds the market earned revenue of
in 2012 and estimates this to reach
in 2019. The analysis covers general infusion pumps (volumetric, syringe, ambulatory, enteral pumps and infusion pump accessories) and insulin infusion pumps.
For more information on this research, please email
, Corporate Communications, at
, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"Since current smart pumps failed to make meaningful improvements in patient safety due to a lack of additional interfaces and software capabilities, market participants are looking to develop wireless, user-friendly smart pumps to enhance patient compliance and facilitate homecare use," said
Frost & Sullivan Healthcare Research Analyst
. "This widens the scope of the infusion pumps market in the U.S."
However, the safety and efficacy of these new technologies are a concern owing to the alarming increase in errors and product recalls, prompting several hospitals to postpone purchases. In addition, the launch of advanced infusion pumps is delayed as regulatory authorities, including the Food and Drug Administration (FDA), take stringent steps to assess the safety parameters of infusion pumps.
The FDA is expected to mandate manufacturers to submit design validations prior to premarket approval. In response, several manufacturers are focusing on product redesign to meet international standards for reliability and risk management.